Logo

Eisai Reports Results of Fycompa (perampanel) in P-III FREEDOM Study for Patients with Newly Diagnosed or Untreated Partial Onset Seizures

Share this

Eisai Reports Results of Fycompa (perampanel) in P-III FREEDOM Study for Patients with Newly Diagnosed or Untreated Partial Onset Seizures

Shots:

  • The P-III FREEDOM study (Study 342) results involve assessing of Fycompa (2mg/day & 4mg/day) as monothx.in 89 patients with newly diagnosed or untreated POS aged ≥12 yrs.
  • The P-III FREEDOM study results: @26wks. 4mg/day- 63% of patients achieved seizure freedom for POS; 65% of patients with generalized seizures are convulsive seizure free
  • Fycompa is a selective- non-competitive AMPA receptor antagonist- available as a film-coated tablet in 2mg- 4mg- 6mg- 8mg- 10mg and 12mg and as a 0.5 mg/mL oral suspension formulation and is approved in 55 countries for multiple epileptic indications

Click here to read full press release/ article | Ref: PRNewsWire | Image: Telangana Today


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions